Addex Therapeutics LTD Schedule 13D activist filings
Filed when an investor crosses five percent and intends to influence the company — the activist disclosure.
NASDAQ
SCHEDULE 13D/A: Addex Therapeutics CEO Timothy Mark Dyer Boosts Stake to 12.94%
Timothy Mark Dyer, CEO of Addex Therapeutics Ltd., has increased his beneficial ownership in the company to 12.94% through a combination of share acquisitions, option exercises, and compensation.